A Phase I, Open Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies
Latest Information Update: 25 Apr 2024
At a glance
- Drugs Selumetinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 22 Apr 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 22 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023
- 26 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.